Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility

Read article

Developing an inhaled drug product

Inhaled drug development

Quotient has a 30 year track record in the development and manufacturing of inhaled drug products. We have experience across a range of drug delivery platforms including dry powder inhalers (DPIs) and solutions/suspensions for inhalation.  With integrated capabilities and vast knowledge of nasal and pulmonary delivery, we help our clients accelerate their molecules from first-in-human, through to proof-of-concept and into full development.
A scientist working the Modu-C capsule filling machine

Integrated capabilities and expertise for nasal and pulmonary delivery

Our extensive expertise and capabilities for nasal and pulmonary delivery include:

  • Pre-formulation and API characterization
  • Formulation and process development
  • Inhaled device evaluation and selection
  • Clinical manufacturing and supply (Phase I-III)
  • Clinical pharmacology assessments

We have a wide range of processing and analytical equipment to support the development and manufacture of inhaled drug products:

  • Spray drying
  • Micronization
  • Blending and encapsulation
  • Aerosol characterization
Ready to get started?
Share your project needs with us.
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.